Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Still trending down

share with twitter share with LinkedIn share with facebook
share via e-mail
07/11/2018 | 03:17am EST
short sell
Target price hit
Entry price : 93.96€ | Target : 88.05€ | Stop-loss : 100€ | Potential : 6.29%
The trend in the price decline should not be put into question for stocks in Bayer over the coming trading sessions given the current chart pattern.
Investors should open a short trade and target the € 88.05.
Duration : Period :
Bayer Technical Analysis Chart | MarketScreener
Full-screen chart
  • The company has poor fundamentals for a short-term investment strategy.

  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 88.91 EUR in weekly data.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

  • The company is in debt and has limited leeway for investment
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the past year, analysts have significantly revised downwards their profit estimates.

Ulrich Ebensperger
© Zonebourse.com 2018
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2018 39 255 M
EBIT 2018 7 484 M
Net income 2018 4 910 M
Debt 2018 38 418 M
Yield 2018 4,26%
P/E ratio 2018 12,21
P/E ratio 2019 14,17
EV / Sales 2018 2,55x
EV / Sales 2019 2,11x
Capitalization 61 511 M
Upcoming event on BAYER
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 90,9 €
Spread / Average Target 38%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER8.92%69 932
JOHNSON & JOHNSON1.27%345 439
PFIZER-3.16%245 166
NOVARTIS4.88%225 489
ROCHE HOLDING LTD.5.59%221 685
MERCK AND COMPANY-0.76%197 187